Trending Topics in Gastroenterology | GastroAGI

Noninvasive Imaging in and IBD

Noninvasive imaging techniques are revolutionizing the diagnosis, monitoring, and management of inflammatory bowel disease (IBD), which includes conditions like Crohn’s disease (CD) and ulcerative colitis (UC). These methods are increasingly favored for their ability to provide accurate assessments without the need for invasive procedures like ileocolonoscopy, which, while considered the gold standard, is often uncomfortable and less repeatable for patients. Below is a comprehensive overview of noninvasive imaging in IBD: --- ### **Key Noninvasive Imaging Modalities** 1. **Intestinal Ultrasound (IUS):** - **Accuracy:** IUS has high sensitivity (~86%) and specificity (~88%) for detecting colonic inflammation, comparable to MRI and CT. - **Advantages:** - Radiation-free, immediate, cost-effective, and suitable for repeated evaluations. - Provides real-time, point-of-care assessment, enabling treatment adjustments during consultations. - Well-suited for monitoring disease activity and tracking transmural remission (TR), which reflects deeper healing beyond mucosal recovery. - **Limitations:** - Reduced accuracy in obese patients and for detecting deep or proximal small bowel lesions. - May require oral contrast or complementary imaging for full evaluation. 2. **Magnetic Resonance Enterography (MRE):** - **Role:** MRE is considered the reference standard for imaging small bowel Crohn’s disease. - **Accuracy:** Near 97% sensitivity and 80% specificity for identifying active disease and complications like strictures, abscesses, and fistulas. - **Advantages:** Provides detailed anatomical imaging without radiation exposure. - **Applications:** Particularly useful for detecting transmural healing and monitoring disease progression or relapse. 3. **Computed Tomography Enterography (CTE):** - **Role:** CTE is an alternative imaging tool, often used when MRE access is limited or in emergencies. - **Advantages:** Accurate and widely accessible. - **Limitations:** Involves radiation exposure, making it less suitable for repeated evaluations. 4. **Video Capsule Endoscopy (VCE):** - **Role:** Excels at detecting small bowel and proximal lesions that may be missed by MRE or IUS. - **Advantages:** Minimally invasive and provides detailed visualization of the bowel mucosa. - **Limitations:** Carries a 3–10% risk of capsule retention, especially in patients with strictures. 5. **Transperineal Ultrasound (TPUS):** - **Role:** Effective for detecting proctitis, rectal wall thickening, and perianal complications in UC and CD. - **Advantages:** Useful for localized disease monitoring, particularly in perianal Crohn’s disease. --- ### **Applications in IBD Management** 1. **Diagnosis:** - Noninvasive imaging methods like IUS, MRE, and CTE provide accurate alternatives for diagnosing IBD. - Combining imaging with biomarkers such as fecal calprotectin (FC) and C-reactive protein (CRP) enhances diagnostic precision, though these biomarkers are not disease-specific. 2. **Monitoring Disease Activity:** - IUS and MRE have >80% sensitivity and specificity for detecting disease relapse or progression. - These methods enable real-time monitoring, allowing clinicians to adjust treatments based on disease activity. 3. **Detection of Complications:** - Imaging techniques are essential for identifying strictures, abscesses, fistulas, and inflammatory masses. - IUS and MRE are particularly effective at differentiating inflammation from fibrosis, guiding appropriate interventions. 4. **Postoperative Assessment:** - IUS, MRE, and VCE are valuable for detecting postoperative recurrence. - IUS demonstrates 82%–88% accuracy compared to colonoscopy in assessing postoperative disease activity. 5. **Perianal Crohn’s Disease:** - MRI remains the preferred tool for evaluating perianal disease and therapy response, offering greater anatomical detail than TPUS or endoanal ultrasound. 6. **Transmural Remission (TR):** - Imaging is increasingly used to assess TR—a deeper indicator of long-term disease control beyond mucosal healing. - IUS and MRE are particularly effective for tracking transmural healing. 7. **Point-of-Care Decisions:** - Bedside IUS has transformed IBD care, allowing clinicians to make immediate treatment decisions and engage patients by visually demonstrating disease progression or improvement. --- ### **Advantages of Noninvasive Imaging in IBD** - **Patient-Friendly:** Reduces the discomfort and invasiveness associated with traditional colonoscopy. - **Repeatable:** Suitable for ongoing monitoring without concerns about radiation exposure (especially with IUS and MRE). - **Cost-Effective:** IUS, in particular, is a sustainable and affordable option for regular assessments. - **Safety:** Noninvasive methods minimize risks while providing reliable diagnostic and monitoring capabilities. - **Improved Outcomes:** Early diagnosis, real-time monitoring, and personalized treatment adjustments contribute to better disease management and patient outcomes. --- ### **Challenges and Limitations** - **IUS:** Accuracy may be compromised in obese patients or for deep/proximal small bowel lesions. - **CTE:** Radiation exposure limits its use for repeated assessments. - **VCE:** Risk of capsule retention in patients with strictures. - **Training Needs:** Structured training programs like IBUS are essential to ensure competency in IUS and other imaging modalities. - **Standardization:** Consistent imaging protocols and structured reporting are necessary to optimize the utility of these techniques. --- ### **Future Innovations** - **Artificial Intelligence (AI):** AI is being integrated into imaging workflows to automate image analysis, improve diagnostic precision, and detect fibrosis. - **Elastography:** Offers potential for detecting fibrosis and further enhancing imaging capabilities. --- ### **Conclusion** Noninvasive imaging has become central to IBD care, replacing or complementing traditional invasive methods for diagnosis and monitoring. Techniques like IUS, MRE, CTE, and VCE provide accurate, patient-friendly, and repeatable solutions that promote early diagnosis, safer monitoring, and personalized management. IUS, in particular, is emerging as the dominant frontline imaging tool globally due to its accessibility, cost-effectiveness, and ability to support point-of-care decisions. As technology advances, innovations like AI and elastography are expected to further enhance the precision and utility of noninvasive imaging in IBD.

Corticosteroids in Clinical Trials in Inflammatory Bowel Disease

Corticosteroids play a significant role in managing inflammatory bowel disease (IBD), but their use in clinical trials has been inconsistent, leading to challenges in interpreting study outcomes. To address this issue, an international consensus was developed to standardize corticosteroid management in randomized controlled trials (RCTs) involving adult patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC). Below is a detailed overview of corticosteroid use in clinical trials for IBD based on the consensus recommendations: ### Purpose of the Consensus The consensus aims to address the heterogeneity in corticosteroid dosing, tapering schedules, and remission definitions across IBD trials. By establishing standardized guidelines, the consensus seeks to: - Minimize prolonged corticosteroid exposure. - Improve patient safety and participation in trials. - Reduce bias in therapeutic outcomes. - Align trial practices with real-world clinical management. ### Key Recommendations for Corticosteroid Use in IBD Trials #### 1. **Corticosteroids During Screening** - Only oral systemic and oral enteric/colonic-release corticosteroids are permitted during the screening phase of the trial. - Patients receiving intravenous corticosteroids during screening are disqualified from participating in the trial. #### 2. **Rectal Corticosteroid Restrictions** - Patients with UC or CD must discontinue rectally administered corticosteroids at least two weeks before screening or randomization. #### 3. **Dose Limitations Before Randomization** - Prednisone-equivalent doses should not exceed **20 mg/day**. - Budesonide doses should not exceed **9 mg/day**. - This ensures participants enter the trial with a manageable corticosteroid exposure level. #### 4. **Stable Dose Period** - Patients must maintain a stable corticosteroid dose for at least **two weeks** prior to baseline or randomization to ensure consistent baseline disease activity. #### 5. **Tapering During Induction** - Tapering of corticosteroids must begin within **two weeks** of randomization. - A fixed tapering rate of **5 mg/week** is recommended for prednisone-equivalent doses. - The tapering schedule should be protocol-defined to ensure uniform application across participants. #### 6. **Defining Treatment Failure** - Patients who start corticosteroids de novo during induction or maintenance phases, or require intravenous rescue therapy, are considered treatment failures. - This definition helps identify patients who do not respond adequately to the trial intervention. #### 7. **Maintenance Phase Guidelines** - Oral corticosteroids should begin tapering at the start of the maintenance phase if tapering has not already been initiated. - Budesonide may be discontinued without tapering during the maintenance phase. #### 8. **Rescue Steroid Use** - Patients requiring more than **one rescue corticosteroid course** during the maintenance phase are deemed treatment failures. - An exception is made for short-term steroid use to manage unrelated conditions, such as asthma. #### 9. **Corticosteroid-Free Remission Definition** - Only patients who were using corticosteroids at the start of the trial should be included in the denominator for calculating corticosteroid-free remission rates. - The consensus debated the withdrawal duration for remission; most experts supported defining remission as withdrawal of corticosteroids for **≥12 weeks** before the final study visit. #### 10. **Standardized Reporting** - The consensus strongly recommends transparent reporting of cumulative corticosteroid exposure, rescue therapy use, and tapering deviations in future trials. - This will improve comparability across studies and provide better insights into therapeutic outcomes. ### Patient Feedback Patients expressed a preference for earlier tapering and minimized steroid use due to adverse effects such as: - Weight gain. - Mood swings. - Sleep disturbances. This feedback highlights the importance of balancing corticosteroid use with patient quality of life during trials. ### Clinical Implications The standardized corticosteroid management framework aims to: - Optimize trial design and execution. - Reduce steroid-related harm. - Enhance the validity and interpretability of therapeutic outcomes. - Align trial practices with real-world clinical scenarios. ### Future Outlook This is the first international corticosteroid management framework specifically designed for IBD RCTs. It is expected to: - Improve patient safety. - Increase trial validity globally. - Serve as a blueprint for future clinical trials focusing on IBD and other inflammatory conditions. ### Scope of Consensus It is important to note that these recommendations apply only to adult patients with moderate-to-severe CD or UC in pharmacologic RCTs. The guidelines do not address pediatric populations or surgical interventions. ### Conclusion The consensus on corticosteroid use in IBD clinical trials represents a groundbreaking effort to harmonize trial protocols, improve patient outcomes, and enhance the reliability of therapeutic evaluations. By implementing these standardized practices, researchers can ensure a consistent approach to corticosteroid management while addressing patient concerns and minimizing adverse effects.

GI infections and IBD Flare

Gastrointestinal (GI) infections are closely linked to flare-ups in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. Here’s a detailed breakdown of the relationship between GI infections and IBD flares: ### 1. **Increased Risk of IBD Flare After GI Infection** - Patients with IBD who experience GI infections are significantly more likely to develop flare-ups within 1–6 months following the infection. Studies show that 37% of infected patients had flare-ups compared to only 11% of non-infected patients. - This suggests that GI infections act as potent inflammatory triggers, exacerbating the underlying disease. ### 2. **Impact on Disease Control and Treatment Intensification** - GI infections often worsen disease control in IBD patients, leading to more frequent treatment escalations. About 37% of infected patients required intensified medication, such as corticosteroids, biologics, or immunosuppressants, compared to 20% of non-infected patients. - This highlights the need for proactive management in infected patients to prevent disease progression. ### 3. **Differences Between Ulcerative Colitis and Crohn’s Disease** - Ulcerative colitis patients appear to be more sensitive to GI infections compared to Crohn’s disease patients. They have higher rates of hospital admissions post-infection, reflecting differing disease responses to inflammatory triggers. ### 4. **Role of Systemic Inflammation (CRP Levels)** - Elevated C-reactive protein (CRP) levels, a marker of systemic inflammation, are strongly associated with worse outcomes in IBD patients with GI infections. High CRP levels significantly increase the likelihood of hospitalization (P = .008), indicating that infections can amplify systemic inflammatory responses. ### 5. **Vulnerability During Early-Stage IBD** - Patients in the early stages of IBD (less than two years since diagnosis) are particularly vulnerable to GI infections. These individuals have 2.3 times greater odds of developing infections compared to those with longer disease durations. - This underscores the importance of vigilant monitoring and preventive strategies in newly diagnosed patients. ### 6. **Common Pathogens in GI Infections** - Key bacterial pathogens associated with GI infections in IBD patients include: - **Campylobacter spp.** - **Yersinia spp.** - **Salmonella spp.** - **Enterohemorrhagic E. coli** - These organisms are known to provoke intestinal inflammation, which can mimic or worsen IBD symptoms. ### 7. **Diagnostic Recommendations** - During an IBD flare, it is crucial to test for bacterial infections as they can either mimic or exacerbate inflammatory activity. Diagnostic methods include: - **Endoscopy:** To visualize inflammation and confirm IBD activity. - **Biopsy-based histology:** To identify tissue changes. - **Biomarkers like fecal calprotectin:** To differentiate between infection and IBD-related inflammation. ### 8. **Post-Infection Monitoring** - Continuous follow-up for at least six months after a GI infection is essential for IBD patients. This monitoring helps detect delayed relapses and allows healthcare providers to optimize treatment strategies. ### 9. **Limitations in Understanding the Relationship** - Current knowledge on the link between GI infections and IBD flares is limited by the retrospective design of studies. Challenges include non-uniform diagnostic records, evolving testing standards, and unclear medication adherence among patients, which complicates establishing causality. ### Clinical Implications: - **Proactive Testing:** During any IBD flare, clinicians should rule out bacterial infections to ensure accurate diagnosis and treatment. - **Early Intervention:** Patients in the early stages of IBD should be monitored more closely for signs of GI infections. - **Treatment Adjustment:** Infected patients may require prompt medication intensification to manage exacerbated disease activity. - **Long-Term Monitoring:** A six-month follow-up post-infection is crucial to detect relapses and improve disease management. In summary, GI infections are a significant risk factor for triggering IBD flares, especially in early-stage patients and those with elevated systemic inflammation. Understanding this relationship is vital for optimizing diagnostic approaches, treatment strategies, and long-term care in IBD patients.

Monogenic Verus Polygenic IBD

Inflammatory Bowel Disease (IBD) is a chronic condition characterized by inflammation in the gastrointestinal tract. It is broadly categorized into two main types: Crohn's Disease (CD) and Ulcerative Colitis (UC). IBD is a complex disorder with genetic, environmental, and immunological factors contributing to its pathogenesis. When discussing the genetic basis of IBD, we often refer to **monogenic** and **polygenic** forms of the disease. Below is a detailed explanation of the differences between these two forms: --- ### **Monogenic IBD** Monogenic IBD refers to cases of IBD caused by mutations in a single gene. These are rare forms of IBD and are typically observed in very early-onset IBD (VEO-IBD), which occurs in children younger than 6 years of age. Monogenic IBD is often associated with severe disease phenotypes and may present atypically compared to the classic forms of Crohn's disease or ulcerative colitis. #### **Key Features of Monogenic IBD:** 1. **Single-Gene Mutation:** - Monogenic IBD results from mutations in a single gene that disrupts immune regulation, intestinal barrier function, or microbial tolerance. - Examples of implicated genes include **IL10**, **IL10RA**, **IL10RB**, **XIAP**, **FOXP3**, **NOD2**, and others. 2. **Early-Onset Disease:** - It is most commonly observed in very young children (VEO-IBD), often within the first few years of life. - Symptoms might be more severe and refractory to conventional treatments. 3. **Immune Dysregulation:** - The mutations often affect pathways involved in immune homeostasis, such as interleukin signaling (e.g., IL-10 signaling defects) or regulatory T-cell function (e.g., FOXP3 mutations). - These defects lead to uncontrolled inflammation and impaired tolerance to gut microbiota. 4. **Diagnostic Approach:** - Genetic testing is essential for identifying monogenic causes. - Whole-exome sequencing (WES) or targeted gene panels are often employed, especially in cases of VEO-IBD or atypical presentations. 5. **Treatment:** - Standard IBD therapies (e.g., immunosuppressants, biologics) may not be effective. - Treatment often involves addressing the underlying genetic defect, which may include hematopoietic stem cell transplantation (HSCT) for severe immune deficiencies. 6. **Examples of Monogenic IBD Disorders:** - **IL10/IL10 receptor mutations:** Lead to severe, early-onset colitis due to defective anti-inflammatory signaling. - **Chronic Granulomatous Disease (CGD):** Caused by mutations in genes affecting the NADPH oxidase complex, leading to impaired microbial killing and granuloma formation. - **IPEX Syndrome:** Caused by mutations in FOXP3, leading to immune dysregulation and severe enteropathy. --- ### **Polygenic IBD** Polygenic IBD refers to the more common forms of IBD (Crohn's disease and ulcerative colitis) that result from the combined effects of multiple genetic variants, each contributing a small risk to disease development. These variants interact with environmental factors, such as diet, smoking, and microbiota composition, to trigger disease onset. #### **Key Features of Polygenic IBD:** 1. **Multiple Genetic Variants:** - Polygenic IBD is associated with variations in multiple genes, each with a modest effect on disease susceptibility. - Genome-wide association studies (GWAS) have identified over **200 genetic loci** associated with IBD. - Examples of implicated genes include **NOD2**, **ATG16L1**, **IL23R**, **IRGM**, and **CARD9**. 2. **Complex Inheritance:** - Unlike monogenic IBD, polygenic IBD does not follow Mendelian inheritance patterns. - The risk is determined by the cumulative effect of genetic variants, often in combination with environmental triggers. 3. **Age of Onset:** - Polygenic IBD typically presents later in childhood, adolescence, or adulthood. - It is the predominant form of IBD seen in clinical practice. 4. **Environmental Influence:** - Environmental factors, such as diet, smoking, infections, and gut microbiota, play a significant role in modulating the risk and course of polygenic IBD. - These factors interact with genetic predispositions to trigger disease onset. 5. **Diagnostic Approach:** - Genetic testing is not routinely used for polygenic IBD diagnosis, as the presence of risk alleles does not guarantee disease development. - Diagnosis is based on clinical presentation, endoscopic findings, and histological examination. 6. **Treatment:** - Management typically involves anti-inflammatory medications, immunosuppressants, and biologics (e.g., anti-TNF agents, anti-integrins, anti-IL12/23 agents). - Lifestyle modifications, dietary interventions, and microbiota-targeted therapies (e.g., probiotics) may also play a role. --- ### **Comparison of Monogenic vs. Polygenic IBD** | **Aspect** | **Monogenic IBD** | **Polygenic IBD** | |---------------------------|--------------------------------------------|-------------------------------------------| | **Cause** | Single gene mutation | Multiple genetic variants with small effects | | **Age of Onset** | Very early (infancy or childhood) | Later childhood, adolescence, or adulthood | | **Prevalence** | Rare | Common | | **Inheritance Pattern** | Mendelian (autosomal dominant/recessive) | Complex, multifactorial | | **Severity** | Often severe and refractory | Variable (mild to severe) | | **Environmental Role** | Minimal | Significant | | **Diagnosis** | Genetic testing (WES, targeted panels) | Clinical evaluation, endoscopy, histology | | **Treatment** | Targeted therapies, HSCT in some cases | Standard IBD therapies, biologics | | **Examples of Genes** | IL10, FOXP3, XIAP, NOD2 | NOD2, ATG16L1, IL23R, CARD9 | --- ### **Clinical Implications** 1. **Importance of Early Diagnosis in Monogenic IBD:** - Early identification of monogenic causes is critical because these patients may require unique treatments, such as HSCT, which can be life-saving. - Delay in diagnosis can lead to significant morbidity and complications. 2. **Personalized Medicine in Polygenic IBD:** - Understanding the genetic basis of polygenic IBD can help identify patients who may benefit from specific therapies, such as biologics targeting IL-23 or TNF-alpha. 3. **Research Opportunities:** - Monogenic IBD provides insights into key pathways involved in intestinal inflammation, which may inform the development of novel therapies for polygenic forms of the disease. - Polygenic IBD research focuses on gene-environment interactions and the role of microbiota in disease pathogenesis. --- ### **Conclusion** Monogenic and polygenic IBD represent two distinct categories of inflammatory bowel disease with differing genetic mechanisms, clinical presentations, and therapeutic approaches. Monogenic IBD is rare, severe, and typically presents in early childhood due to single-gene defects affecting immune regulation. Polygenic IBD, on the other hand, is more common and results from the cumulative effects of multiple genetic variants interacting with environmental factors. Understanding these differences is crucial for accurate diagnosis, appropriate treatment, and advancing research into the underlying mechanisms of IBD.

IL-23 inhibitors and IBD

IL-23 inhibitors represent a significant advancement in the treatment landscape for inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC). These biologic agents target the interleukin-23 (IL-23) cytokine, specifically its p19 subunit, which plays a crucial role in driving the chronic inflammation underlying IBD. By selectively inhibiting IL-23, these therapies aim to reduce inflammation, promote mucosal healing, and improve patient outcomes. ### **Role of IL-23 in IBD Pathogenesis** IL-23 is a pro-inflammatory cytokine that is part of the IL-12 family. It is composed of two subunits: p19 (unique to IL-23) and p40 (shared with IL-12). IL-23 is produced by antigen-presenting cells such as dendritic cells and macrophages and plays a central role in the differentiation and maintenance of Th17 cells, a subset of CD4+ T cells. Th17 cells, in turn, produce inflammatory cytokines like IL-17, IL-22, and TNF-α, which contribute to the inflammation and tissue damage seen in IBD. By targeting the p19 subunit, IL-23 inhibitors selectively block IL-23 signaling without affecting IL-12, thereby preserving the protective immune functions of IL-12. ### **Approved IL-23 Inhibitors for IBD** Several IL-23 inhibitors have demonstrated efficacy and safety in clinical trials and are either approved or under investigation for the treatment of IBD: 1. **Risankizumab**: - Approved for moderate-to-severe Crohn’s disease. - Clinical trials (e.g., ADVANCE and MOTIVATE) have shown significant improvements in clinical remission, endoscopic response, and quality of life in patients with CD. - Demonstrated a favorable safety profile with low rates of infections and adverse events. 2. **Mirikizumab**: - Recently approved for moderate-to-severe ulcerative colitis. - Clinical trials (e.g., LUCENT-1 and LUCENT-2) showed significant efficacy in inducing and maintaining clinical remission, endoscopic improvement, and histologic remission in UC patients. - Safety data suggest a low risk of serious infections and adverse events. 3. **Guselkumab**: - Currently approved for psoriasis and psoriatic arthritis, with ongoing trials for Crohn’s disease (e.g., GALAXI-1). - Preliminary data suggest promising efficacy and safety in CD. 4. **Tildrakizumab**: - Primarily approved for psoriasis but being investigated for IBD. - Early-phase trials are ongoing to evaluate its effectiveness in CD and UC. ### **Efficacy of IL-23 Inhibitors** Clinical trials and real-world studies have demonstrated the efficacy of IL-23 inhibitors in both induction and maintenance phases of treatment: - **Induction Phase**: IL-23 inhibitors have shown rapid reductions in disease activity, with many patients achieving clinical remission and endoscopic improvement within 8-12 weeks. - **Maintenance Phase**: These agents have demonstrated sustained efficacy over long-term treatment, with many patients maintaining remission and mucosal healing for up to a year or longer. ### **Safety Profile** IL-23 inhibitors have a favorable safety profile compared to other biologics. Key findings include: - Low risk of serious infections. - Minimal immunosuppression compared to anti-TNF agents. - Rare adverse events, with most being mild-to-moderate in severity (e.g., upper respiratory tract infections, injection site reactions). ### **Position in Treatment Algorithm** According to the **American Gastroenterological Association (AGA)** and **European Crohn’s and Colitis Organisation (ECCO)** guidelines, IL-23 inhibitors are increasingly being positioned as a valuable option in the treatment of IBD: 1. **Moderate-to-Severe Crohn’s Disease**: - IL-23 inhibitors, such as risankizumab, are recommended for patients who have failed conventional therapies (e.g., corticosteroids, immunomodulators) or other biologics (e.g., anti-TNF agents, anti-IL-12/23 agents like ustekinumab). - They are also considered for biologic-naïve patients due to their targeted mechanism of action and favorable safety profile. 2. **Moderate-to-Severe Ulcerative Colitis**: - Mirikizumab is recommended for patients with inadequate response or intolerance to conventional or biologic therapies. - Emerging data suggest that IL-23 inhibitors may be particularly effective in patients with a higher inflammatory burden, as evidenced by elevated biomarkers like CRP and fecal calprotectin. 3. **Combination Therapy**: - Preliminary evidence suggests that IL-23 inhibitors may be used in combination with other biologics (e.g., anti-TNF agents) or small-molecule drugs (e.g., JAK inhibitors like tofacitinib or upadacitinib) to achieve deeper remission in refractory cases. - However, more research is needed to establish the safety and efficacy of combination regimens. ### **Advantages Over Other Biologics** IL-23 inhibitors offer several advantages over existing biologics: - **Selective Targeting**: By targeting the IL-23p19 subunit, these agents avoid inhibiting IL-12, which plays a protective role in immune defense against infections and malignancies. - **Durable Remission**: IL-23 inhibitors have demonstrated sustained efficacy in maintaining remission and mucosal healing, even in patients who have failed other biologics. - **Convenient Dosing**: Most IL-23 inhibitors are administered subcutaneously every 4-8 weeks, offering convenience and improved patient adherence. ### **Challenges and Future Directions** Despite their promise, IL-23 inhibitors face several challenges: - **Cost**: Like other biologics, IL-23 inhibitors are expensive, which may limit access for some patients. - **Long-Term Safety**: While short-term safety data are reassuring, long-term safety, particularly regarding the risk of infections or malignancies, needs further evaluation. - **Biomarker Development**: Identifying biomarkers to predict response to IL-23 inhibitors remains an area of active research, with the goal of personalizing treatment for individual patients. ### **Conclusion** IL-23 inhibitors represent a major advancement in the management of IBD, addressing unmet needs for patients with moderate-to-severe disease who do not respond adequately to existing therapies. With their targeted mechanism of action, robust efficacy, and favorable safety profile, these agents are poised to play a central role in personalized treatment strategies for Crohn’s disease and ulcerative colitis. Ongoing research, including head-to-head trials and studies exploring combination therapies, will further clarify their place in the therapeutic landscape and expand the possibilities for improving patient outcomes.

Gut inflammation and axial spondyloarthritis –SPARTAKUS cohor

The relationship between gut inflammation and axial spondyloarthritis (axSpA) has been extensively studied, and the SPARTAKUS cohort plays a key role in advancing our understanding of this association. Below is a detailed explanation of the gut-joint hypothesis, the influence of gut inflammation on joint inflammation, and the significance of the SPARTAKUS cohort in studying these phenomena. --- ### **Gut-Joint Hypothesis** The gut-joint hypothesis posits that inflammation in the gut can influence inflammation in distant sites like the spine and joints, contributing to the development and progression of diseases such as axial spondyloarthritis (axSpA). This connection is thought to occur through several mechanisms: 1. **Immune System Crosstalk**: - The gut is a central hub for immune system regulation. Dysbiosis (imbalance in gut microbiota) or subclinical gut inflammation can lead to aberrant activation of immune pathways, particularly the IL-23/IL-17 axis, which is implicated in axSpA pathogenesis. - These inflammatory cytokines can travel through the bloodstream and contribute to systemic inflammation, including inflammation in the joints and spine. 2. **Molecular Mimicry**: - Certain gut microbial antigens may resemble self-antigens, leading to an autoimmune response that targets both the gut and musculoskeletal system. 3. **Leaky Gut Syndrome**: - Gut inflammation can result in increased intestinal permeability ("leaky gut"), allowing microbial products like lipopolysaccharides (LPS) to enter the bloodstream and trigger systemic inflammation. 4. **Shared Genetic Susceptibility**: - Genetic factors like HLA-B27, which are strongly associated with axSpA, may also predispose individuals to gut inflammation, creating a bidirectional relationship between gut health and musculoskeletal disease. --- ### **How Gut Inflammation Influences Joint Inflammation** Gut inflammation, as measured by biomarkers like fecal calprotectin (F-calprotectin), has been shown to correlate with joint and spinal inflammation in axSpA. Key mechanisms include: 1. **Cytokine Pathways**: - Elevated gut inflammation activates pro-inflammatory cytokines such as IL-17, IL-23, and TNF-alpha, which are directly involved in the chronic inflammation seen in axSpA. - These cytokines promote the recruitment of immune cells to the joints and spine, leading to inflammation and structural damage. 2. **Systemic Inflammatory Burden**: - Persistent gut inflammation contributes to an overall heightened inflammatory state, which can exacerbate joint and spinal damage over time. 3. **Subclinical Gut Inflammation**: - Even in the absence of overt symptoms of inflammatory bowel disease (IBD), subclinical gut inflammation (detected via elevated F-calprotectin) can influence musculoskeletal disease severity in axSpA patients. 4. **Radiographic Progression**: - Studies, including the SPARTAKUS cohort, have demonstrated that elevated F-calprotectin levels are independently associated with greater structural spinal damage, as measured by the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). This suggests that gut inflammation contributes to long-term radiographic progression in axSpA. --- ### **SPARTAKUS Cohort and Its Importance** The SPARTAKUS cohort is a population-based study conducted in southern Sweden, involving 228 patients with well-characterized axial spondyloarthritis (axSpA). Its primary goal is to investigate the underlying mechanisms, clinical characteristics, and progression of axSpA, with a particular focus on gut inflammation. #### **Key Features of the SPARTAKUS Cohort**: 1. **Large Sample Size**: - The cohort includes 228 patients, divided into non-radiographic axSpA (nr-axSpA, n=76) and radiographic axSpA (r-axSpA, n=152) groups. This allows researchers to explore disease differences across varying severity levels. 2. **Comprehensive Data Collection**: - Participants are well-characterized, with detailed information on demographics, genetic markers (e.g., HLA-B27), disease activity scores (ASDAS, BASDAI), imaging (mSASSS), and biomarkers like fecal calprotectin and C-reactive protein (CRP). 3. **Focus on Gut Inflammation**: - The cohort specifically examines the role of gut inflammation in axSpA progression, using F-calprotectin as a biomarker to assess subclinical intestinal inflammation. 4. **Robust Statistical Analysis**: - The study adjusts for confounding factors such as sex, smoking, NSAID use, TNF inhibitor therapy, and comorbidities like inflammatory bowel disease (IBD), ensuring the reliability of its findings. #### **Significance of SPARTAKUS Cohort Findings**: 1. **Gut-Spine Connection**: - The study provides strong evidence for the gut-joint axis hypothesis, showing that elevated F-calprotectin levels are independently associated with greater structural spinal damage in axSpA. 2. **Radiographic Progression**: - Patients with higher F-calprotectin levels consistently exhibit more severe radiographic damage, particularly in the r-axSpA subgroup. This highlights the potential of gut inflammation as a driver of disease progression. 3. **Clinical Correlations**: - Elevated F-calprotectin levels are also associated with higher CRP levels, longer symptom duration, and higher disease activity scores (ASDAS, BASDAI), reinforcing the role of inflammation in cumulative spinal damage. 4. **IBD Independence**: - The association between gut inflammation and spinal damage persists even after excluding patients with IBD, suggesting that subclinical gut inflammation alone can contribute to axSpA severity. 5. **Diagnostic and Prognostic Utility**: - F-calprotectin testing may serve as a non-invasive biomarker for identifying patients at risk of progressive spinal ankylosis, aiding in early intervention and personalized treatment strategies. 6. **Pathophysiological Insights**: - The study supports the hypothesis that gut inflammation, possibly mediated by the IL-23/IL-17 pathway, plays a central role in axSpA pathogenesis and progression. --- ### **Future Directions** The SPARTAKUS cohort findings underscore the need for further research into the gut-joint axis in axSpA. Future studies should focus on: 1. **Longitudinal Analysis**: - Tracking patients over time to determine whether elevated F-calprotectin predicts future radiographic progression. 2. **Intervention Trials**: - Investigating whether targeting gut inflammation (e.g., through dietary modification, probiotics, or anti-inflammatory therapies) can alter spinal outcomes in axSpA. 3. **Advanced Imaging**: - Incorporating spinal MRI data to directly assess concurrent inflammatory activity and structural damage. 4. **Mechanistic Studies**: - Exploring the molecular pathways linking gut and joint inflammation, particularly the role of microbiota and cytokines like IL-23 and IL-17. --- ### **Conclusion** The SPARTAKUS cohort has provided compelling evidence that gut inflammation, as measured by fecal calprotectin, is independently associated with greater structural spinal damage in axial spondyloarthritis. These findings highlight the gut’s central role in disease pathogenesis and progression, supporting the gut-joint hypothesis. F-calprotectin testing may emerge as a valuable tool for predicting radiographic progression and guiding personalized treatment strategies, emphasizing the need for further research into the gut-joint axis in axSpA.

Oral lyophilized donor FMT in ulcerative colitis

**Oral Lyophilized Donor FMT in Ulcerative Colitis:** Oral lyophilized donor fecal microbiota transplantation (FMT) involves encapsulated, freeze-dried fecal microbiota from a healthy donor, designed for oral administration. This innovative approach simplifies the logistics of FMT compared to traditional frozen formulations, providing a practical, non-invasive treatment option. The goal of FMT is to restore microbial diversity and balance in the gut, which is often disrupted in ulcerative colitis (UC). UC is a chronic inflammatory bowel disease characterized by dysbiosis—reduced microbial diversity and loss of beneficial short-chain fatty acid-producing bacteria, such as Faecalibacterium prausnitzii and Akkermansia muciniphila. Dysbiosis contributes to intestinal inflammation, impaired barrier function, and disease progression. The study investigated oral lyophilized FMT in mild-to-moderate UC patients, showing promising results. FMT significantly increased gut microbial diversity, shifting the microbiome toward the donor’s composition. Key beneficial taxa, such as Clostridium SGB6179, Faecalibacterium prausnitzii, and Alistipes finegoldii, engrafted efficiently into patients' microbiomes, promoting anti-inflammatory effects and epithelial repair. Functional changes included enhanced microbial pathways for L-citrulline biosynthesis and the urea cycle, vital for intestinal repair and immune modulation. Clinically, 53% of FMT-treated patients achieved corticosteroid-free remission with endoscopic response by week 8, compared to 15% in the placebo group. Long-term low-dose FMT maintained remission for up to 56 weeks. Furthermore, FMT reduced antibiotic resistance gene abundance, restoring a healthier resistome profile. This study highlights oral lyophilized FMT as an effective, accessible therapy for UC, paving the way for targeted microbial therapeutics in chronic inflammatory bowel diseases.

Upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK

The real-world study on upadacitinib in patients with moderate-to-severe Crohn’s disease (CD) was conducted across 19 hospitals in the UK between April and October 2023. The study aimed to evaluate the effectiveness, persistence, and safety of upadacitinib in a challenging cohort of patients with active CD. Below is a detailed overview of the study findings: ### Study Design and Patient Cohort: 1. **Multicentre Retrospective Cohort Study**: The study involved data collection from 19 hospitals in the UK. 2. **Patient Population**: Included 312 adults with active moderate-to-severe Crohn’s disease. - 64% of patients had failed three or more biologic therapies, indicating a highly refractory population. - 51% had penetrating or stricturing disease, which are more severe phenotypes of Crohn’s disease. ### Effectiveness: 1. **Primary Endpoint**: Clinical remission was defined as a Harvey Bradshaw Index (HBI) score of <4, assessed at 12 and 24 weeks. 2. **Induction Remission** (12 weeks): - 50% (113/227) of patients achieved clinical remission. - Of those achieving remission, 93% were steroid-free, highlighting the efficacy of upadacitinib without reliance on corticosteroids. 3. **Maintenance Remission** (24 weeks): - 45% (77/172) of patients maintained clinical remission. - 96% of these patients were steroid-free. 4. **Biochemical Remission**: - Faecal calprotectin and C-reactive protein (CRP) levels normalized in 28% of patients by week 12 and 18% by week 24. 5. **Endoscopic Remission**: - Mucosal healing (endoscopic remission) was slower compared to symptomatic improvements, with 6% achieving remission at 12 weeks and 12% at 24 weeks. ### Persistence: 1. **Drug Persistence**: Upadacitinib showed strong adherence and tolerability. - Persistence rates were 90.3% at 12 weeks and 84.1% at 24 weeks. ### Predictors of Remission: 1. **Disease Location**: - Patients with colonic (L2) and ileocolonic (L3) disease had higher odds of remission compared to those with isolated ileal (L1) disease. - Colonic disease was the strongest predictor of remission (OR 9.16, p=0.003), followed by ileocolonic disease (OR 3.44, p=0.043). 2. **Smoking Status**: - Ex-smokers had significantly lower odds of achieving remission compared to never-smokers (OR 0.08, p=0.006). 3. **Stoma Patients**: - Patients with stomas had reduced remission rates due to limitations in the Harvey Bradshaw Index (HBI), which does not accurately measure stool frequency in stoma patients. 4. **Early Response**: - Early response was predictive of long-term success; 80% of patients in remission at 12 weeks remained in remission at 24 weeks. ### Safety Profile: 1. **Adverse Events (AEs)**: - AEs were reported in 28% of patients, with 18% experiencing serious AEs. - The most frequent AEs included infections (7.7%) and lipid abnormalities (4.8%). 2. **Severe Events**: - Serious AEs included resections (5.4%), symptom worsening (4.8%), obstructions (2.2%), and venous thromboembolism (1%). 3. **Discontinuation Rate**: - 8% of patients discontinued upadacitinib due to side effects, which aligns with rates observed in prior real-world studies. ### Comparison with Clinical Trials: - Remission rates in this real-world study (45%) were consistent with results from clinical trials such as U-EXCEL and U-EXCEED (39–50%), validating the efficacy of upadacitinib in real-world settings. ### Limitations: 1. **Retrospective Design**: The study's retrospective nature may introduce biases. 2. **Incomplete Endoscopy Data**: Limited availability of endoscopic data restricts the ability to comprehensively assess mucosal healing. 3. **Challenges in Stoma Patients**: Difficulty in quantifying outcomes for stoma patients due to limitations in the HBI scoring system. ### Conclusion: Upadacitinib demonstrated good short-term effectiveness, strong drug persistence, and an acceptable safety profile in a highly refractory population of Crohn’s disease patients in the UK. The study supports upadacitinib as an effective oral therapy for moderate-to-severe Crohn’s disease in real-world clinical practice. Despite certain limitations, the findings align closely with clinical trial data, further validating the use of upadacitinib in managing this chronic inflammatory condition.

Psychological interventions and IBD Management

Psychological interventions have been increasingly recognized as valuable components in the management of inflammatory bowel disease (IBD). This is because IBD is not only a physical condition but also closely intertwined with psychological and emotional well-being. The study you provided offers a comprehensive analysis of various psychological interventions and their effectiveness in addressing key outcomes such as depression, anxiety, stress, disease activity, and quality of life (QoL) in individuals with IBD. Here is a detailed breakdown of the role of psychological interventions in IBD management based on the study findings: ### 1. **Psychological Interventions Evaluated** The study analyzed 12 psychological interventions, including: - **Mindfulness Interventions (MI)** - **Cognitive Behavioral Therapy (CBT)** - **Acceptance and Commitment Therapy (ACT)** - **Multicomponent ACT (compassion-focused)** - **Hypnotherapy** - **Relaxation Training** - **Psychoeducation** These interventions aim to address the psychological challenges often faced by IBD patients, such as depression, anxiety, and stress, which can exacerbate disease symptoms and reduce quality of life. --- ### 2. **Key Psychological Outcomes** The study focused on three primary psychological outcomes—depression, anxiety, and stress—and their management through various interventions: #### **Depression** - **Mindfulness Interventions (MI)** and **CBT** were found to significantly reduce depressive symptoms compared to waiting list (WL) controls. - MI had the strongest effect (Standardized Mean Difference [SMD]: −0.63) and ranked the highest in effectiveness (SUCRA: 77.2%). - Mechanism: MI likely reduces depressive symptoms by promoting emotional regulation, reducing rumination, and fostering acceptance. Neuroimaging evidence supports that MI induces positive changes in brain regions associated with mood regulation. #### **Anxiety** - **ACT**, **Multicomponent ACT (compassion-focused)**, and **CBT** were the most effective interventions for reducing anxiety: - Multicomponent ACT had the strongest effect (SMD: −1.15), followed by ACT (SMD: −1.01) and CBT (SMD: −0.75). - Mechanism: ACT-based therapies work by increasing psychological flexibility and encouraging self-acceptance through mindfulness and value-based actions. #### **Stress** - **CBT** emerged as the most effective intervention for stress reduction, achieving the top SUCRA ranking (97.2%), followed by ACT (78.1%) and psychoeducation (74.7%). - Mechanism: CBT targets stress by addressing maladaptive thought patterns and behaviors and incorporating relaxation techniques. --- ### 3. **Quality of Life (QoL)** - **Mindfulness Interventions (MI)** were particularly effective in improving health-related QoL: - MI significantly enhanced QoL compared to WL controls (SMD: 2.21) and usual care (SMD: 1.82), ranking the highest overall (SUCRA: 99.9%). - This suggests that mindfulness practices can play a transformative role in improving the overall well-being of IBD patients. --- ### 4. **Disease Activity** - No psychological intervention showed a statistically significant improvement in disease activity. However, **Multicomponent ACT** ranked highest in SUCRA (90.4%). - While psychological therapies may not directly impact disease activity, they can indirectly influence disease outcomes by addressing the brain–gut axis. Psychosocial stress and neuroimmune responses are known to contribute to IBD exacerbations, highlighting the importance of psychological care. --- ### 5. **Mechanistic Insights** The study emphasizes the role of the brain–gut axis in IBD management. Psychological interventions likely influence this axis by: - Reducing psychosocial stress, which is a known trigger for IBD flare-ups. - Modulating neuroimmune responses that contribute to inflammation. - Enhancing emotional regulation, which can mitigate the impact of chronic stress on disease progression. --- ### 6. **Limitations of Current Research** While the study provides valuable insights, it also highlights several limitations that should be addressed in future research: - Small sample sizes in the included randomized controlled trials (RCTs). - Lack of blinding and allocation concealment in many studies, which may introduce bias. - Reliance on waiting list (WL) controls rather than active comparators, which limits the robustness of conclusions. - Heterogeneity among the interventions analyzed, making it challenging to generalize findings. --- ### 7. **Clinical Implications** - Psychological therapies should be considered **adjunctive treatments** rather than replacements for traditional IBD treatments such as pharmacological and surgical interventions. - These therapies are particularly effective for improving quality of life and managing emotional outcomes (depression, anxiety, and stress) in IBD patients. - Tailored psychological interventions can help address individual patient needs. For instance: - **Mindfulness Interventions** are most effective for depression and QoL. - **ACT-based therapies** are highly effective for managing anxiety. - **CBT** is the leading intervention for stress management. --- ### 8. **Future Research Directions** The study calls for further research to address the limitations and enhance the understanding of the long-term benefits of psychological interventions in IBD management. Recommendations include: - Conducting large multicenter RCTs with robust designs. - Direct head-to-head comparisons of different psychological interventions. - Standardizing outcome measures across studies. - Incorporating objective biomarkers to assess the impact of psychological interventions on disease activity and progression. --- ### 9. **Conclusion** The study highlights the importance of integrating psychological interventions into the care of IBD patients, aligning with a biopsychosocial model of treatment. While traditional medical therapies remain essential for managing disease activity, psychological therapies can significantly enhance emotional well-being and quality of life. Tailoring interventions to address specific psychological challenges (e.g., depression, anxiety, stress) can improve overall outcomes for individuals living with IBD.

Therapy of iPSC-derived CD146+ mesenchymal stem cells in ulcerative colitis

The study explored the therapeutic potential of induced pluripotent stem cell-derived CD146+ mesenchymal stem cells (CD146+iMSCs) for treating ulcerative colitis (UC). These stem cells were compared to CD146+ umbilical cord mesenchymal stem cells (UCMSCs) in terms of biological traits, anti-inflammatory effects, and immune modulation mechanisms. CD146+iMSCs demonstrated stronger proliferation, self-renewal, and differentiation abilities, maintaining classical mesenchymal stem cell markers. They effectively shifted macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, showing superior immune modulation compared to CD146+UCMSCs. Transcriptome analysis revealed that CD146+iMSCs upregulated pathways involved in calcium signaling, TGF-β, and immune regulation, while suppressing TNF signaling, enhancing their anti-inflammatory activity. In a UC mouse model, CD146+iMSCs significantly alleviated symptoms, reduced weight loss, restored colon length, repaired intestinal barriers, and improved mucosal architecture. They reduced inflammatory cytokines (IL-6, TNF-α, IL-1β) and normalized immune cell populations, restoring immune homeostasis. The study identified the suppression of the IL-17 signaling pathway as a critical mechanism for UC treatment. Additionally, nine key inflammatory hub genes were downregulated by CD146+iMSCs, further supporting their anti-inflammatory effects. CD146+iMSCs also regulated the cGAS-STING pathway, promoting immune tolerance and enhancing mucosal healing. Their regenerative effects were linked to genes involved in tissue repair (TGFB2, CXCL12, VEGF, FGF). Intraperitoneal injection provided better therapeutic outcomes by improving biodistribution to inflamed sites. Overall, CD146+iMSCs demonstrated robust regenerative, anti-inflammatory, and immunomodulatory potential, offering a promising therapy for UC through immune regulation and tissue repair mechanisms.